ORALLY BIOAVAILABLEβ-LACTAM/β-LACTAMASE INHIBITOR COMBINATION FOR BIODEFENSE AND PUBLIC HEALTH.
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN272201600029C
- Awardee
-
Venatorx Pharmaceuticals Inc. UEI MBBKNBU5DCC6
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $48,517,079
Award facts
- Opportunity
-
- NIAIDDMIDNIHAI2015037 Solicitation number
- Development of Therapeutic Products for Biodefense & Emerging Infectious Diseases Award Notice · Posted Jun 17, 2015
- Contract value 100% obligated
- $48,517,078.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 13 offers Basic Research
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Malvern, PA 19355, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$60,728 | |
| Funding Only Action | -$195,932 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | -$94,723 | |
| Supplemental Agreement for work within scope | $370,321 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $3,344,053 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $2,284,288 | |
| Funding Only Action | -$1 | |
| Exercise an Option | $3,975,473 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $439,651 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $1,926,565 | |
| Supplemental Agreement for work within scope | $1,155,623 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $1,369,025 | |
| Exercise an Option | $7,234,848 | |
| Exercise an Option | $2,522,045 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $1,169,969 | |
| Funding Only Action | $2,828,870 | |
| Exercise an Option | $3,974,779 | |
| Funding Only Action | $9,174,369 | |
| Other Administrative Action | $0 | |
| Original award | $7,098,583 |
Show all 31
About this award
The National Institute of Allergy and Infectious Diseases awarded a $48.5 million definitive contract to Venatorx Pharmaceuticals Inc. for the development of orally bioavailable β-lactam/β-lactamase inhibitor combinations for biodefense and public health on September 19, 2016, under no set-aside.
This award is primarily an obligation action: the contract de-obligates unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a), with an ultimate completion date of March 31, 2026. Place of performance is Malvern, PA. The contract is priced on a cost-plus-fixed-fee basis.
Service Contract Inventory reporting shows the contract's labor footprint contracted significantly over its performance period. FY2021 invoiced $7.9 million across 6.7 FTEs and 13,832 contractor hours. By FY2025, invoicing had declined to $2.1 million with 2.0 FTEs and 4,138 contractor hours. The government-paid blended hourly rate varied substantially year to year, ranging from $254.10/hr (FY2024) to $2,127.32/hr (FY2023), with an overall declining trend. In FY2025, Venatorx subcontracted 65% of contractor hours to one reported subcontractor.
Quick answers
Who was awarded contract HHSN272201600029C?
HHSN272201600029C was awarded to Venatorx Pharmaceuticals Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 19, 2016.
How much is contract HHSN272201600029C worth?
The government has obligated $48,517,079 on HHSN272201600029C.
Was contract HHSN272201600029C competed?
The extent of competition for HHSN272201600029C was full and open competition. The government received 13 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award